Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma
Cancer Medicine · 2025
DOI: 10.1002/cam4.70445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Katsuya Toshida und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Aim
With advances in systemic therapy, the number of patients with hepatocellular carcinoma (HCC) who can undergo hepatic resection has increased in recent years, but there are no reports evaluating the immune status in the peritumoral area.
Methods
We enrolled 14 patients who underwent hepatic resection after lenvatinib (LEN, n = 7) or atezolizumab plus bevacizumab (ATZ/BEV, n = 5) therapy. Tumor‐infiltrating lymphocytes (TILs), including CD3+ and CD8+ TILs, in the peritumoral area were evaluated by hematoxylin and eosin staining and immunohistochemistry.
Results
The median TIL counts after LEN and ATZ/BEV therapy were 32 and 92 cells/0.237 mm 2 , respectively ( p = 0.0044). The median CD3+ TIL counts after LEN and ATZ/BEV therapy were 26 and 71 cells/0.237 mm 2 , respectively ( p = 0.0057). The median CD8+ TIL counts after LEN and ATZ/BEV therapy were 14 and 42 cells/0.237 mm 2 , respectively ( p = 0.0044).
Conclusion
TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Shinji Itoh, Takeo Toshima, Shohei Yoshiya, Takeshi Iwasaki
Förderung
- JSPS KAKENHI
Zitieren
APA
Toshida, K., Itoh, S., Tanaka, Y., Toshima, T., Yoshiya, S., Izumi, T., Iseda, N., Tsutsui, Y., Nakayama, Y., Ishikawa, T., Ninomiya, M., Iwasaki, T., Oda, Y., & Yoshizumi, T. (2025). Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70445
Vancouver
Toshida K, Itoh S, Tanaka Y, Toshima T, Yoshiya S, Izumi T, et al. Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70445
BibTeX
@article{Toshida2025,
author = {Toshida, Katsuya and Itoh, Shinji and Tanaka, Yasushi and Toshima, Takeo and Yoshiya, Shohei and Izumi, Takuma and Iseda, Norifumi and Tsutsui, Yuriko and Nakayama, Yuki and Ishikawa, Takuma and Ninomiya, Mizuki and Iwasaki, Takeshi and Oda, Yoshinao and Yoshizumi, Tomoharu},
title = {Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70445}
}
EUVIMED